Fluoxetine treatment for major depression decreases the plasma levels of cytokines

African Journal of Biotechnology

Volumn 9, Issue 43, 2010, Pages 7346-7351

  Shen, Yuedi ^a   Lu, Peilin ^b   Wei, Lili ^b   Cai, Liqiang ^b   Hu, Xingyue ^b   Chen, Wei ^b  

^a HANGZHOU NORMAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Chemokine; Cytokine; Fluoxetine hydrochloride; Inflammation; Major depression

Indexed keywords

CYTOKINE; FLUOXETINE; INTERLEUKIN 18; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAMILTON SCALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SOMATIZATION;

EID: 78549245114     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, Ayala AR, Licinio J, Gold HK, Kling MA, Chrousos GP, Gold PW (2005). Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm and loss of physiological complexity in its secretion: clinical implications. J. Clin. Endocrinol. Metab. 90: 2522-2530.
2. Bosker FJ, Westerink BH, Cremers TI, Gerrits M, van der Hart MG, Kuipers SD, van der Pompe G, ter Horst GJ, den Boer JA, Korf J (2004). Future antidepressants: what is in the pipeline and what is missing? CNS Drugs, 18: 705-732.
3. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG (1991). Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 294: 425-435.
4. Byrne SE, Rothschild AJ (1998). Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J. Clin. Psychiatry, 59:279-288.
5. Connor TJ, Leonard BE (1998). Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62: 583-606.
6. Curran B, O'Connor JJ (2001). The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptormediated transmission in the rat hippocampus in vitro. Neuroscience, 108: 83-90.
7. Kokai M, Kashiwamura S, Okamura H, Ohara K, Morita Y (2002). Shen et al. 7351 Plasma interleukin-18 levels in patients with psychiatric disorders. J. Immunother. 25: 68-71.
8. Lehto SM, Niskanen L, Herzig KH, Tolmunen T, Huotari A, Viinamäki H, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Hintikka J (2010). Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology, 5: 226-232.
9. Lekakis J, Ikonomidis I, Papoutsi Z, Moutsatsou P, Nikolaou M, Parissis J, Kremastinos DT (2010). Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int. J. Cardiol. 139: 150-158.
10. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006). Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 367: 1747-1757.
11. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine, 9: 853-858.
12. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect Disord. 34: 301-309.
13. Maes M, Meltzer HY, Buckley P, Bosmans E (1995). Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur. Arch. Psychiatry Clin. Neurosci. 244: 325-329.
14. Merendino RA, Di Pasquale G, De Luca F, Di Pasquale L, Ferlazzo E, Martino G, Palumbo MC, Morabito F, Gangemi S (2004). Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression. Mediators Inflamm. 13: 205-207.
15. Merendino RA, Di Rosa AE, Di Pasquale G, Minciullo PL, Mangraviti C, Costantino A, Ruello A, Gangemi S (2002). Interleukin-18 and CD30 serum levels in patients with moderate-severe depression. Mediators Inflamm. 11: 265-267.
16. Muller T, Dürk T, Blumenthal B, Grimm M, Cicko S, Panther E, Sorichter S, Herouy Y, Di Virgilio F, Ferrari D, Norgauer J, Idzko M (2009). 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One, 4: e6453.
17. Nelson JC (2003). Managing treatment-resistant major depression. J. Clin. Psychiatry, 64: 5-12.
18. Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, Devane CL (2009). Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J. Biol Psychiatry, 10: 313-323.
19. Shini S, Kaiser P (2009). Effects of stress, mimicked by administration of corticosterone in drinking water, on the expression of chicken cytokine and chemokine genes in lymphocytes. Stress, 12: 388-399.
20. Sutcigi L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, Sanisoglu SY, Yesilova Z, Ozmenler N, Ozsahin A, Sengul A (2007). Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin. Dev. Immunol. 2007: 76396.
21. Taler M, Bar M, Korob I, Lomnitski L, Baharav E, Grunbaum-Novak N, Weizman A, Gil-Ad I (2008). Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactiveimmune disorders. Int. Immunopharmacol. 8: 526-533.
22. Wang J, Dunn AJ (1999). The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1 beta. Brain Res. 815: 337-348.
23. Yasui T, Yamada M, Uemura H, Ueno S, Numata S, Ohmori T, Tsuchiya N, Noguchi M, Yuzurihara M, Kase Y, Irahara M (2009). Changes in circulating cytokine levels in midlife women with psychological symptoms with selective serotonin reuptake inhibitor and Japanese traditional medicine. Maturitas, 62: 146-152.
24. Zhu J, Wei X, Liu J, Hu Y, Xu J (2009). Interaction of glia activation and neurotransmission in hippocampus of neuropathic rats treated with mirtazapine. Exp. Clin. Psychopharmacol. 17: 198-203.